

Remarks

Upon entry of the foregoing amendment, claims 41-230 are pending in the application, with claims 41 and 136 being the independent claims. Claims 1-40 are being canceled without prejudice to or disclaimer of the subject matter therein. Applicants reserve the right to pursue the subject matter of claims 1-40 in one or more continuing applications. New claims 41-230 are sought to be added. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Support for the new claims can be found throughout the specification and original claims. For example, support for independent claims 41 and 136 can be found in original claim 37 and in the specification at page 8, lines 23-25. Support for the dependent claims can be found, for example, in SI:Q ID NOS:23-114 and in the specification at pages 35-39, page 28, lines 6-19 and page 31, lines 1-26.

Statement Under 37 C.F.R. § 1.63(d)(2)

As required under 37 C.F.R. § 1.63(d)(2), Applicants hereby request the deletion of Marco Baggioini from the inventorship of the above-captioned application. This change in inventorship is necessitated by the above amendment deleting claims 1-40. As Marco Baggioini is not an inventor of the subject matter of any of the added claims, his deletion from the inventorship is believed proper.

10/22/02
JL/MS
CJL

Conclusion

Applicants believe that this application is now in condition for substantive examination. Early notice to this effect is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date:

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Versions with Markings to show changes made

In the Inventorship:

Brent L. Kreider, Steven M. Ruben, Henrik S. Olsen, [Marco Baggolini]

In the Title:

Page 1, line 1:

Methods of Using Chemokine β -6.

In the Specification:

The paragraph beginning at page 1, line 2:

This application is a divisional of U.S. Application No. 09 419,281, filed October 15, 1999, which is a divisional [continuation] of U.S. Application No. 08 995,156, filed December 19, 1997 [now U.S. Patent No. 6,028,169], presently allowed], which claims the benefit of U.S. Provisional Application No. 60 042,269, filed March 31, 1997], both of which disclosures are herein incorporated by reference]. All of said applications are herein incorporated by reference.

In the claims:

Claims 1-40 have been cancelled.

Claims 41-230 have been newly added.